医学
细胞因子释放综合征
淋巴瘤
免疫学
CD22
抗原
嵌合抗原受体
皮肤T细胞淋巴瘤
体内
CD19
阿勒姆图祖马
细胞因子
临床试验
药理学
免疫疗法
旁观者效应
内科学
细胞毒性
疾病
肿瘤科
药品
最大耐受剂量
滤泡性淋巴瘤
癌症研究
Blinatumoab公司
临床研究阶段
免疫刺激剂
CD52型
免疫系统
白血病
效力
抗体
CD20
体外
毒性
作者
Sumithira Vasu,Nathan Denlinger,No‐Joon Song,Danielle Elsberry,Qiuhong Zhao,Lianbo Yu,Evandro D. Bezerra,Nicole Szuminski,Dina Schneider,Pradyot Dash,Louisa Wirthlin,Narendranath Epperla,Yazeed Sawalha,Jennifer Ann Woyach,Shamama Nishat,Kerry Anne Rogers,Seema Ali Bhat,Hazem E. Ghoneim,Gregory K. Behbehani,Timothy J. Voorhees
出处
期刊:Blood cancer discovery
[American Association for Cancer Research]
日期:2026-07-14
卷期号:7 (5): 711-725
被引量:1
标识
DOI:10.1158/2643-3230.bcd-26-0186
摘要
Disease recurrence is the main cause of treatment failure after CD19-directed chimeric antigen receptor (CAR) T cells, often due to CD19 antigen loss, stability, and/or coverage. To overcome single-antigen escape, we evaluated a trispecific CAR targeting CD19, CD20, and CD22 with an OX40 costimulatory domain. Preclinical studies demonstrated potent, antigen-specific cytotoxicity in in vitro and in vivo lymphoma models. We then conducted a first-in-human phase I trial in patients with relapsed/refractory B-cell malignancies. Sixteen patients received infusions at a median vein-to-vein time of 7 days, at doses of 0.5 to 2 × 106 cells/kg. No severe cytokine release syndrome or neurotoxicity occurred. The overall response rate was 50%, including complete responses in 83% of patients with lymphoma. The 1-year overall survival rate was 61%, with durable remissions observed in lymphoma. CAR T expansion did not correlate with dose or response. T-cell exhaustion in apheresis cells correlated with progressive disease. Trispecific CAR T cells are safe and potentially active in lymphoma. SIGNIFICANCE: This first-in-human trial demonstrates that point-of-care manufactured trispecific CD19/20/22 CAR T cells with OX40 costimulation can be rapidly produced, safely administered, and induce durable remissions in relapsed B-cell lymphoma. Findings highlight multispecific targeting to mitigate antigen escape and identify T-cell exhaustion as a key biomarker guiding future CAR T optimization. See related commentary by Merz and Luttwak, p. 652.
科研通智能强力驱动
Strongly Powered by AbleSci AI